

Global Precision Medicine Market: Focus on Precision Medicine Ecosystem, Applications, 13 Countries Mapping, and Competitive Landscape - Analysis and Forecast: 2018-2028

<https://marketpublishers.com/r/G29969471DC6EN.html>

Date: January 2019

Pages: 544

Price: US\$ 5,000.00 (Single User License)

ID: G29969471DC6EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Various advancements in the life sciences industry have paved the way for development of several precision medicine solutions. It is one of the most modernized trends in the healthcare industry that has projected tremendous level of progress in the last few years. The completion of the Human Genome project in 2003 and the precision medicine initiative in 2015 provided a path of opportunity to introduce new scientific, medical, and business models in the precision medicine market. The sole idea behind the development of precision medicine solution is to provide targeted therapies to population based on their genomic structure. Therefore, the application of 'omics' (genomics, proteomics, transcriptomics) analysis is widely used in this market. The precision medicine market is a multibillion market which consists of innumerable companies involved in the research and development, manufacturing and commercialization of several novel drugs and diagnostic kits to boost the Precision Medicine workflow.

Currently, the precision medicine market is gaining preference among the masses due to the growth of personal healthcare devices and integration of smart technologies in the healthcare system. In addition, increasing collaborations and partnerships between various ecosystem players are aiding in the robust growth of the precision medicine market. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging),

government support and regulations, which consequently, have created a demand for the precision medicine solutions. Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The primary aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases, among others.

The purpose of this study is to gain a holistic view of the precision medicine market in terms of various influencing factors, such as recent trends, technological advancements, and role of various key stakeholders in the market. The report constitutes an in-depth study of the global precision medicine market, including a thorough analysis of the products across different regions. The study also presents a detailed analysis of the market trends, and the market size for the period 2017-2028, wherein 2017 is the base year, and the years from 2018 to 2028 constitute the forecast period. The report covers all the prevalent trends which are expected to play a significant role in the growth of the market over the forecast period. It also highlights various drivers, restraints, challenges, and opportunities which are expected to influence the market's growth during the forecast period. The report is focused on the global precision medicine market; ecosystem and technology, application, their market dynamics, growth prospect mapping, SWOT analysis, Porter's Five Forces, market share analysis, pipeline analysis, and country-wise analysis.

The study provides a holistic perspective on the market growth, in terms of revenue estimates, across different geographies which include North America, Europe, Asia-Pacific (APAC), Latin America, and Rest of the World (RoW). The report provides cross-sectional analysis of the global precision medicine market in terms of market estimates, and projections, for all the segments across different geographical regions. The regions have been further segmented to cover the in-depth country level analysis. The North American region has been segmented into the U.S., and Canada. Similarly, Europe has been further segmented into the U.K., Germany, France, Spain, Italy, and Rest of Europe. Asia Pacific has been segmented into China, Japan, Australia, India, and Rest of Asia Pacific. Latin America has been segmented into Brazil, Mexico, and Rest of Latin America. Moreover, Rest of the World (RoW) has been further segmented into Middle East and Africa.

Key questions answered in the report:

What are the major market drivers, challenges, and opportunities in the global precision medicine market?

What are the underlying structures resulting in the emerging trends within the precision medicine market?

What was the market value of the leading segments and sub-segments of the global precision medicine market in 2017?

How will each segment of the global precision medicine market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2028?

What are the influencing factors that may affect the market share of the key players?

How will the industry evolve during the forecast period 2018- 2028?

What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?

What are the key ecosystem type in the global precision medicine market? What are the major benefits of each type?

How has the market been segmented on the basis of application type? Which application type is dominating the global precision medicine market and what is the reason behind such domination?

Which ecosystem type is having the most promising growth and in which application type?

What is the market share of each of the companies in the global precision medicine market and what are their contributions?

What is the scope of each type of ecosystem in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?

What is the growth potential of precision medicine in each region, including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?

How many countries are covered in each geographical region? Which country is

currently dominating the precision medicine market?

The key players which have been contributing significantly to the precision medicine market include Abbott Laboratories, Almac Group, Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, ASURAGEN, INC., bioMerieux SA, BRISTOL-MYERS SQUIBB COMPANY, CETICS Healthcare Technologies GmbH, Eli-Lilly and Company, F. Hoffmann-La Roche AG, GE Healthcare, GlaxoSmithKline, IBM Corporation, Illumina, Inc., Intomics A/S, JOHNSON & JOHNSON, Laboratory Corporation of America, Merck KGaA, Novartis AG, Pfizer, Inc., QIAGEN, Quest Diagnostics, SANOFI, Teva Pharmaceuticals Limited, and Thermo Fisher Scientific, among others.

Contents

EXECUTIVE SUMMARY

1 MARKET OVERVIEW

- 1.1 Introduction
- 1.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine
- 1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
- 1.4 Initiatives and Programs
- 1.5 Assumptions and Limitations for Market Size Calculations
- 1.6 Precision Medicine: Enabling Technologies
 - 1.6.1 Innovators
 - 1.6.1.1 3D DNA Printing
 - 1.6.1.1.1 Introduction
 - 1.6.1.1.2 Role of 3D DNA Printing
 - 1.6.1.2 RNA-Seq
 - 1.6.1.2.1 Introduction
 - 1.6.1.2.2 Role of RNA-Seq in Precision Medicine
 - 1.6.1.2.3 Key Players
 - 1.6.1.3 4D Molecular Imaging
 - 1.6.1.3.1 Introduction
 - 1.6.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
 - 1.6.1.3.3 Key Players
 - 1.6.2 Early Adopters
 - 1.6.2.1 CRISPR
 - 1.6.2.1.1 Introduction
 - 1.6.2.1.2 Role of CRISPR in Precision Medicine
 - 1.6.2.1.3 Key Players
 - 1.6.2.2 Blockchain
 - 1.6.2.2.1 Introduction
 - 1.6.2.2.2 Role of Blockchain in Precision Medicine
 - 1.6.2.2.3 Key Players
 - 1.6.2.3 Imaging Informatics
 - 1.6.2.3.1 Introduction
 - 1.6.2.3.2 Role of Imaging Informatics in Precision Medicine
 - 1.6.2.3.3 Key Players
 - 1.6.3 Early Majority

- 1.6.3.1 Artificial Intelligence (AI)
 - 1.6.3.1.1 Introduction
 - 1.6.3.1.2 Role of Artificial Intelligence in Precision Medicine
 - 1.6.3.1.3 Key Players
- 1.6.3.2 Circulating free DNA (cfDNA)
 - 1.6.3.2.1 Introduction
 - 1.6.3.2.2 Role of cfDNA in Precision Medicine
 - 1.6.3.2.3 Key Players
- 1.6.3.3 Big Data
 - 1.6.3.3.1 Introduction
 - 1.6.3.3.2 Role of Big Data in Precision Medicine
 - 1.6.3.3.3 Key Players
- 1.6.3.4 Next-Generation Sequencing (NGS)
 - 1.6.3.4.1 Introduction
 - 1.6.3.4.2 Role of NGS in Precision Medicine
 - 1.6.3.4.3 Key Players
- 1.6.3.5 Health Informatics
 - 1.6.3.5.1 Introduction
 - 1.6.3.5.2 Role of Health informatics in Precision Medicine
 - 1.6.3.5.3 Key players
- 1.6.3.6 Bioinformatics
 - 1.6.3.6.1 Introduction
 - 1.6.3.6.2 Role of Bioinformatics in Precision Medicine
 - 1.6.3.6.3 Key Players
- 1.6.4 Late Majority
 - 1.6.4.1 Polymerase Chain Reactions (PCR)
 - 1.6.4.1.1 Introduction
 - 1.6.4.1.2 Role of PCR in Precision Medicine
 - 1.6.4.1.3 Key players
 - 1.6.4.2 Microarray
 - 1.6.4.2.1 Role of Microarray in Precision Medicine
 - 1.6.4.2.2 Key Players

2 MARKET DYNAMICS

- 2.1 Impact Analysis
- 2.2 Market Drivers
 - 2.2.1 Advancement of Sequencing Technologies
 - 2.2.2 Rising Prevalence of Chronic Diseases

- 2.2.3 Growing Demand for Preventive Care
- 2.2.4 Shifting the Significance in Medicine, from Reaction to Prevention
- 2.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test
- 2.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe
- 2.3 Market Restraints
 - 2.3.1 Unified Framework for Data Integration
 - 2.3.2 Limited Knowledge About Precision Medicine Application
 - 2.3.3 Lack of Robust Reimbursement Landscape
 - 2.3.4 Regulatory Hurdles
- 2.4 Market Opportunities
 - 2.4.1 Targeted Gene Therapy
 - 2.4.2 Expansion into the Emerging Markets
 - 2.4.3 Collaboration and Partnerships Across Value Chain Would Accelerate the Market Entry

3 COMPETITIVE INSIGHTS

- 3.1 Key Developments and Strategies
 - 3.1.1 Joint Ventures, Partnerships, Agreements, and Collaborations
 - 3.1.2 Product launches, Enhancements, and Upgradation
 - 3.1.3 Product Approvals
 - 3.1.4 Merger and Acquisitions
 - 3.1.5 Business Expansion
 - 3.1.6 Other Developments
- 3.2 Market Share Analysis
 - 3.2.1 Market Share Analysis by Applied Sciences, 2017
 - 3.2.2 Market Share Analysis by Precision Diagnostics, 2017
 - 3.2.3 Market Share Analysis by Precision Therapeutics, 2017
 - 3.2.4 Market Share Analysis by Digital Health and IT, 2017
- 3.3 Industry Attractiveness
 - 3.3.1 Definition of Suppliers and Buyers in the Precision Medicine Market
 - 3.3.2 Bargaining Power of Suppliers
 - 3.3.3 Bargaining Power of Buyers
 - 3.3.4 Threat of New Entrants
 - 3.3.5 Threat of Substitute Products
 - 3.3.6 Intensity of Competitive Rivalry
- 3.4 Supply Chain Analysis

4 INDUSTRY INSIGHTS

- 4.1 Patent Analysis
- 4.2 Legal Requirements and Regulations
- 4.3 Pipeline Analysis

5 GLOBAL PRECISION MEDICINE MARKET (BY ECOSYSTEM)

- 5.1 Overview
- 5.2 Applied Sciences
 - 5.2.1 Genomics
 - 5.2.1.1 Polymerase Chain Reaction (PCR)
 - 5.2.1.2 Precision Medicine Next-Generation Sequencing (PM NGS)
 - 5.2.1.3 Genome Editing
 - 5.2.1.4 Other Technologies
 - 5.2.2 Pharmacogenomics
 - 5.2.3 Other Applied Sciences
- 5.3 Precision Diagnostics
 - 5.3.1 Molecular Diagnostics (MDx)
 - 5.3.1.1 Non-invasive Prenatal Testing (NIPT)
 - 5.3.1.2 Companion Diagnostics
 - 5.3.1.3 Liquid Biopsy
 - 5.3.1.4 Other Molecular Diagnostics
 - 5.3.2 Medical Imaging
 - 5.3.2.1 Imaging Analytics
 - 5.3.2.2 Imaging Computer-Aided Detection (CADx)
- 5.4 Digital Health and Information Technology
 - 5.4.1 Clinical Decision Support Systems (CDSS)
 - 5.4.2 Big Data Analytics
 - 5.4.3 IT Infrastructure
 - 5.4.4 Genomics Informatics
 - 5.4.5 In-Silico Informatics
 - 5.4.6 Mobile Health
- 5.5 Precision Therapeutics
 - 5.5.1 Clinical Trials
 - 5.5.2 Cell Therapy
 - 5.5.3 Drug Discovery and Research
 - 5.5.4 Gene Therapy

6 GLOBAL PRECISION MEDICINE MARKET (BY APPLICATION)

- 6.1 Overview
- 6.2 Oncology
 - 6.2.1 Government Initiatives
 - 6.2.2 Key Insights
 - 6.2.3 Drivers and Challenges
 - 6.2.4 Cancer Precision Medicine Drugs and Indications
 - 6.2.5 Recent Key Developments
- 6.3 Infectious Diseases
 - 6.3.1 Infectious Diseases Precision Medicine Drugs and Indications
- 6.4 Neurology/Physiatry
 - 6.4.1 Neurology Precision Medicine Drugs and Indications
- 6.5 Cardiovascular
 - 6.5.1 Cardiovascular Precision Medicine Drugs/Tests/ and Indications
- 6.6 Lifestyle and Endocrinology
 - 6.6.1 Endocrinology Precision Medicine Drugs and Indications
- 6.7 Gastroenterology
 - 6.7.1 Gastroenterology Precision Medicine Drugs and Indications
- 6.8 Other Applications
 - 6.8.1 Precision Drugs for Other Applications

7 GLOBAL PRECISION MEDICINE MARKET (BY REGION)

- 7.1 Overview
- 7.2 North America
 - 7.2.1 North America Precision Medicine Market Dynamics
 - 7.2.2 The U.S.
 - 7.2.2.1 Market Statistics
 - 7.2.2.2 Overview of Precision Medicine
 - 7.2.2.3 Key Trends
 - 7.2.2.4 Promoting Factors
 - 7.2.2.5 Recent Key Developments
 - 7.2.2.6 Funding Scenario/Investments
 - 7.2.2.7 Regulatory Scenario
 - 7.2.2.8 Key Players
 - 7.2.3 Canada
 - 7.2.3.1 Market Statistics
 - 7.2.3.2 Overview of Precision Medicine
 - 7.2.3.3 Key Trends

- 7.2.3.4 Promoting Factors
- 7.2.3.5 Recent Key Developments
- 7.2.3.6 Funding Scenario
- 7.2.3.7 Regulatory Scenario
- 7.2.3.8 Key Players

7.3 Europe

7.3.1 Europe Precision Medicine Market Dynamics

7.3.2 Germany

- 7.3.2.1 Market Statistics
- 7.3.2.2 Overview of Precision Medicine
- 7.3.2.3 Key Trends
- 7.3.2.4 Promoting Factors
- 7.3.2.5 Recent Key Developments
 - 7.3.2.5.1 Key Players

7.3.3 France

- 7.3.3.1 Market Statistics
- 7.3.3.2 Overview of Precision Medicine
- 7.3.3.3 Key Trends
- 7.3.3.4 Promoting Factors
- 7.3.3.5 Recent Key Developments
- 7.3.3.6 Key Players

7.3.4 Italy

- 7.3.4.1 Market Statistics
- 7.3.4.2 Overview of Precision Medicine
- 7.3.4.3 Key Trends
- 7.3.4.4 Promoting Factors
- 7.3.4.5 Recent Key Developments
- 7.3.4.6 Funding Scenario/Investments

7.3.5 The U.K.

- 7.3.5.1 Market Statistics
- 7.3.5.2 Overview of Precision Medicine
- 7.3.5.3 Key Trends
- 7.3.5.4 Promoting Factors
- 7.3.5.5 Recent Key Developments
- 7.3.5.6 Funding Scenario/Investments
- 7.3.5.7 Key Players

7.3.6 Spain

- 7.3.6.1 Market Statistics
- 7.3.6.2 Overview of Precision Medicine

- 7.3.6.3 Key Trends
- 7.3.6.4 Promoting Factors
- 7.3.6.5 Recent Key Developments
- 7.3.6.6 Key Players
- 7.3.7 Rest-of-Europe
 - 7.3.7.1 Market Statistics
 - 7.3.7.2 Switzerland
- 7.4 Asia-Pacific (APAC)
 - 7.4.1 Asia-Pacific Precision Medicine Market Dynamics
 - 7.4.1.1 China
 - 7.4.1.2 Market Statistics
 - 7.4.1.3 Overview of Precision Medicine
 - 7.4.1.4 Key Trends
 - 7.4.1.5 Promoting Factors
 - 7.4.1.6 Recent Key Developments
 - 7.4.1.7 Key Players
 - 7.4.2 Japan
 - 7.4.2.1 Market Statistics
 - 7.4.2.2 Overview of Precision Medicine
 - 7.4.2.3 Key Trends
 - 7.4.2.4 Promoting Factors
 - 7.4.2.5 Recent Key Developments
 - 7.4.2.6 Reimbursement Scenario
 - 7.4.2.7 Key Players
 - 7.4.3 Australia
 - 7.4.3.1 Market Statistics
 - 7.4.3.2 Overview of Precision Medicine
 - 7.4.3.3 Key Trends
 - 7.4.3.4 Promoting Factors
 - 7.4.3.5 Recent Key Developments
 - 7.4.3.6 Regulatory Scenario
 - 7.4.3.7 Key Players
 - 7.4.4 India
 - 7.4.4.1 Market Statistics
 - 7.4.4.2 Overview of Precision Medicine
 - 7.4.4.3 Key Trends
 - 7.4.4.4 Promoting Factors
 - 7.4.4.5 Recent Key Developments
 - 7.4.4.6 Key Players

7.4.5 Rest-of-Asia-Pacific (RoAPAC)

7.4.5.1 Market Statistics

7.4.5.2 Singapore

7.4.5.2.1 Regulatory Framework

7.4.5.3 South Korea

7.4.5.4 Vietnam

7.5 Latin America

7.5.1 Latin America Precision Medicine Market Dynamics

7.5.2 Brazil

7.5.2.1 Market Statistics

7.5.2.2 Overview of Precision Medicine

7.5.3 Mexico

7.5.3.1 Market Statistics

7.5.3.2 Overview of Precision Medicine

7.5.3.3 Recent Key Developments

7.5.4 Rest-of-Latin America (RoLA)

7.5.4.1 Market Statistics

7.6 Rest-of-the-World (RoW)

7.6.1 Market Statistics

7.6.1.1 Middle East Precision Market Dynamics

7.6.1.2 Africa Precision Medicine Market Dynamics

7.6.1.3 Israel

7.6.1.4 Saudi Arabia

7.6.1.5 United Arab Emirates

7.6.1.6 South Africa

7.6.1.7 Russia

8 COMPANY PROFILE

8.1 Abbott Laboratories.

8.1.1 Company Overview

8.1.2 Role of Abbott Laboratories, Inc.in the Global Precision Medicine Market

8.1.3 Key Insights about Financial Health of the Company

8.1.4 SWOT Analysis

8.2 Almac Group Ltd.

8.2.1 Company Overview

8.2.2 Role of Almac Group Ltd. in the Global Precision Medicine Market

8.2.3 SWOT Analysis

8.3 Amgen Inc.

- 8.3.1 Company Overview
- 8.3.2 Role of Amgen Inc. in the Global Precision Medicine Market
- 8.3.3 Key Insights about Financial Health of the Company
- 8.3.4 SWOT Analysis
- 8.4 ANGLE plc
 - 8.4.1 Company Overview
 - 8.4.2 Role of ANGLE plc in the Global Precision Medicine Market
 - 8.4.3 Key Insights about Financial Health of the Company
 - 8.4.4 SWOT Analysis
- 8.5 Astellas Pharma Inc.
 - 8.5.1 Company Overview
 - 8.5.2 Role of Astellas Pharma Inc.in the Global Precision Medicine Market
 - 8.5.3 Key Insights about Financial Health of the Company
 - 8.5.4 SWOT Analysis
- 8.6 Astra Zeneca PLC
 - 8.6.1 Company Overview
 - 8.6.2 Role of Astra Zeneca PLC in the Global Precision Medicine Market
 - 8.6.3 Key Insights about Financial Health of the Company
 - 8.6.4 SWOT Analysis
- 8.7 ASURAGEN INC.
 - 8.7.1 Company Overview
 - 8.7.2 Role of ASURAGEN Inc. in the Global Precision Medicine Market
 - 8.7.3 SWOT Analysis
- 8.8 Bio-Rad Laboratories, Inc.
 - 8.8.1 Company Overview
 - 8.8.2 Role of Bio-Rad Laboratories, Inc.in the Global Precision Medicine Market
 - 8.8.3 Key Insights about Financial Health of the Company
 - 8.8.4 SWOT Analysis
- 8.9 bioM?rieux SA.
 - 8.9.1 Company Overview
 - 8.9.2 Role of bioM?rieux SA. in the Global Precision Medicine Market
 - 8.9.3 Key Insights about Financial Health of the Company
 - 8.9.4 SWOT Analysis
- 8.10 Bristol-Myers Squibb Company
 - 8.10.1 Company Overview
 - 8.10.2 Role of Bristol-Myers Squibb Company in the Global Precision Medicine Market
 - 8.10.3 Key Insights about Financial Health of the Company
 - 8.10.4 SWOT Analysis
- 8.11 Canon Inc.

- 8.11.1 Company Overview
- 8.11.2 Role of Canon Inc. in the Global Precision Medicine Market
- 8.11.3 Key Insights about Financial Health of the Company
- 8.11.4 SWOT Analysis
- 8.12 CETICS Healthcare Technologies GmbH
 - 8.12.1 Company Overview
 - 8.12.2 Role CETICS Healthcare Technologies GmbH in the Global Precision Medicine Market
 - 8.12.3 Figure SWOT Analysis
- 8.13 Danaher Corporation
 - 8.13.1 Company Overview
 - 8.13.2 Role of Danaher Corporation in the Global Precision Medicine Market
 - 8.13.3 Key Insights about Financial Health of the Company
 - 8.13.4 SWOT Analysis
- 8.14 Eli Lilly and Company Limited
 - 8.14.1 Company Overview
 - 8.14.2 Role of Eli Lilly and Company Limited in the Global Precision Medicine Market
 - 8.14.3 Key Insights about Financial Health of the Company
 - 8.14.4 SWOT Analysis
- 8.15 Epic Sciences, Inc.
 - 8.15.1 Company Overview
 - 8.15.2 Role Epic Sciences, Inc. in the Global Precision Medicine Market
 - 8.15.3 SWOT Analysis
- 8.16 F. Hoffmann-La Roche AG
 - 8.16.1 Company Overview
 - 8.16.2 Role of F.Hoffman-LA Roche AG in the Global Precision Medicine Market
 - 8.16.3 Key Insights about Financial Health of the Company
 - 8.16.4 SWOT Analysis
- 8.17 GE Corporation
 - 8.17.1 Company Overview
 - 8.17.2 Role of GE Corporation in the Global Precision Medicine Market
 - 8.17.3 Key Insights about Financial Health of the Company
 - 8.17.4 SWOT Analysis
- 8.18 Gilead Sciences, Inc.
 - 8.18.1 Company Overview
 - 8.18.2 Role of Gilead Sciences, Inc. in the Global Precision Medicine Market
 - 8.18.3 Key Insights about Financial Health of the Company
 - 8.18.4 SWOT Analysis
- 8.19 GlaxoSmithKline Plc

- 8.19.1 Company Overview
- 8.19.2 Role of GlaxoSmithKline Plc in the Global Precision Medicine Market
- 8.19.3 Key Insights about Financial Health of the Company
- 8.19.4 SWOT Analysis
- 8.20 IBM Corporation
 - 8.20.1 Company Overview
 - 8.20.2 Role of IBM Corporation in the Global Precision Medicine Market
 - 8.20.3 Key Insights about Financial Health of the Company
 - 8.20.4 SWOT Analysis
- 8.21 Illumina, Inc.
 - 8.21.1 Company Overview
 - 8.21.2 Role of Illumina, Inc. in the Global Precision Medicine Market
 - 8.21.3 Key Insights about Financial Health of the Company
 - 8.21.4 SWOT Analysis
- 8.22 Intomics A/S
 - 8.22.1 Company Overview
 - 8.22.2 Role Intomics A/S in the Global Precision Medicine Market
 - 8.22.3 SWOT Analysis
- 8.23 Johnson & Johnson
 - 8.23.1 Company Overview
 - 8.23.2 Role of Johnson and Johnson in the Global Precision Medicine Market
 - 8.23.3 Key Insights about Financial Health of the Company
 - 8.23.4 SWOT Analysis
- 8.24 Konica Minolta, Inc.
 - 8.24.1 Company Overview
 - 8.24.2 Role of Konica Minolta, Inc. in the Global Precision Medicine Market
 - 8.24.3 Key Insights about Financial Health of the Company
 - 8.24.4 SWOT Analysis
- 8.25 Laboratory Corporation of America
 - 8.25.1 Company Overview
 - 8.25.2 Role of Lab Corporation of America in the Global Precision Medicine Market
 - 8.25.3 Key Insights about Financial Health of the Company
 - 8.25.4 SWOT Analysis
- 8.26 MDxHealth, Inc.
 - 8.26.1 Company Overview
 - 8.26.2 Role of MDx Health, Inc. in the Global Precision Medicine Market
 - 8.26.3 Key Insights about Financial Health of the Company
 - 8.26.4 SWOT Analysis
- 8.27 Menarini Silicon Biosystems, Inc.

- 8.27.1 Company Overview
- 8.27.2 Role Menarini Silicon Biosystems, Inc. in the Global Precision Medicine Market
- 8.27.3 SWOT Analysis
- 8.28 Merck & Co., Inc.
 - 8.28.1 Company Overview
 - 8.28.2 Role of Merck & Co., Inc. in the Global Precision Medicine Market
 - 8.28.3 Key Insights about Financial Health of the Company
 - 8.28.4 SWOT Analysis
- 8.29 Myriad Genetics, Inc.
 - 8.29.1 Company Overview
 - 8.29.2 Role of Myriad Genetics, Inc. in the Global Precision Medicine Market
 - 8.29.3 Key Insights about Financial Health of the Company
 - 8.29.4 SWOT Analysis
- 8.30 Novartis AG.
 - 8.30.1 Company Overview
 - 8.30.2 Role of Novartis AG in the Global Precision Medicine Market
 - 8.30.3 Key Insights about Financial Health of the Company
 - 8.30.4 SWOT Analysis
- 8.31 Oracle Corporation.
 - 8.31.1 Company Overview
 - 8.31.2 Role of Oracle Corporation in the Global Precision Medicine Market
 - 8.31.3 Key Insights about Financial Health of the Company
 - 8.31.4 SWOT Analysis
- 8.32 Pacific Biosciences of California, Inc.
 - 8.32.1 Company Overview
 - 8.32.2 Role of Pacific Biosciences of California, Inc. in the Global Precision Medicine Market
 - 8.32.3 Key Insights about Financial Health of the Company
 - 8.32.4 SWOT Analysis
- 8.33 Partek, Inc.
 - 8.33.1 Company Overview
 - 8.33.2 Role Partek, Inc. in the Global Precision Medicine Market
 - 8.33.3 SWOT Analysis
- 8.34 Pfizer, Inc.
 - 8.34.1 Company Overview
 - 8.34.2 Role of Pfizer, Inc. in the Global Precision Medicine Market
 - 8.34.3 Key Insights about Financial Health of the Company
 - 8.34.4 SWOT Analysis
- 8.35 QIAGEN N.V

- 8.35.1 Company Overview
- 8.35.2 Role of QAIGEN N.V in the Global Precision Medicine Market
- 8.35.3 Key Insights about Financial Health of the Company
- 8.35.4 SWOT Analysis
- 8.36 Quest Diagnostics Inc.
 - 8.36.1 Company Overview
 - 8.36.2 Role of Quest Diagnostics Inc. in the Global Precision Medicine Market
 - 8.36.3 Key Insights about Financial Health of the Company
 - 8.36.4 SWOT Analysis
- 8.37 Randox Laboratories Ltd.
 - 8.37.1 Company Overview
 - 8.37.2 Role of Randox Laboratories Ltd. in the Global Precision Medicine Market
 - 8.37.3 SWOT Analysis
- 8.38 Sanofi SA
 - 8.38.1 Company Overview
 - 8.38.2 Role of Sanofi SA in the Global Precision Medicine Market
 - 8.38.3 Key Insights about Financial Health of the Company
 - 8.38.4 SWOT Analysis
- 8.39 Sysmex Corporation
 - 8.39.1 Company Overview
 - 8.39.2 Role of Sysmex Corporation in the Global Precision Medicine Market
 - 8.39.3 Key Insights about Financial Health of the Company
 - 8.39.4 SWOT Analysis
- 8.40 Teva Pharmaceuticals Industries Ltd.
 - 8.40.1 Company Overview
 - 8.40.2 Role of Teva Pharmaceuticals Industries Ltd. in the Global Precision Medicine Market
 - 8.40.3 Key Insights about Financial Health of the Company
 - 8.40.4 SWOT Analysis
- 8.41 Thermo Fisher Scientific, Inc.
 - 8.41.1 Company Overview
 - 8.41.2 Role of Thermo Fisher Scientific Inc. in the Global Precision Medicine Market
 - 8.41.3 Key Insights about Financial Health of the Company
 - 8.41.4 SWOT Analysis
- 8.42 TrovaGene, Inc.
 - 8.42.1 Company Overview
 - 8.42.2 Role of TrovaGene, Inc. in the Global Precision Medicine Market
 - 8.42.3 SWOT Analysis

9 REPORT SCOPE AND METHODOLOGY

- 9.1 Scope of the Report
- 9.2 Research Methodology
 - 9.2.1 Primary Research
 - 9.2.2 Secondary Research
 - 9.2.3 Key Data Points from Primary Resources
 - 9.2.4 Key Data Points from Secondary Sources
 - 9.2.5 Data Triangulation

10 LIST OF ANNEXURES

- 10.1 Recent Key Developments and Strategies
- 10.2 Product Mapping
- 10.3 Patent Analysis
- 10.4 Funding Scenario
- 10.5 List of Precision Medicine Drugs
- 10.6 Patent Landscape and Regulatory Bodies
- 10.7 Cancer Incidence Datasheet
- 10.8 List of Approved Products
- 10.9 Competitive Mapping
- 10.10 PM Initiatives
- 10.11 List of Universities
- 10.12 List of Prominent Center of Excellence (CoE)
- 10.13 Data on Partnerships by Academics, CoE and Industry
- 10.14 Precision Medicine Drugs Pipeline Analysis

List Of Tables

LIST OF TABLES

Table 1: Comparison of China and the U.S. Healthcare Statistics

Table 1.1: Initiatives and Programs

Table 2.1: Impact Analysis

Table 2.2: Percentage of Total Regional Aged Population (65 years & above: 2015 & 2030)

Table 2.3: Cancer Incidence by WHO Region, 2012 (Thousands)

Table 2.4: Cancer Incidence Type in Thousand, 2012 (WHO)

Table 2.5: Policy and Guidance Documents from the U.S. FDA

Table 4.1: Pipeline Analysis

Table 4.2: Precision Medicine Drugs Pipeline Analysis

Table 5.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling

Table 5.2: Key Approved Therapeutics with FDA Mandated Companion Diagnostics Tests

Table 5.3: List of FDA Approved Companion Diagnostics

Table 5.4: Commercially Available Primary and Secondary Analysis Tools Providers

Table 6.1: Cancer Precision Medicine Drugs and Indications

Table 6.2: Recent Key Developments

Table 6.3: Infectious Diseases Precision Medicine Drugs and Indications

Table 6.4: Neurology Precision Medicine Drugs and Indications

Table 6.5: Cardiovascular Precision Medicine Drugs/Tests/ and Indications

Table 6.6: Endocrinology Precision Medicine Drugs and Indications

Table 6.7: Gastroenterology Precision Medicine Drugs and Indications

Table 6.8: Precision Drugs for Other Applications

Table 7.1: Funding scenario in Universities

List Of Figures

LIST OF FIGURES

Figure 1: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure

Figure 2: Precision Medicine – a Multi-Faceted Approach to Patient Care

Figure 3: Chronic Conditions: Key Statistics: 2017

Figure 4: Long-Term Growth Drivers

Figure 5: Impact Analysis

Figure 6: Global Precision Medicine Market Snapshot

Figure 7: Dominating Segments of Global Precision Medicine Market, 2017 and 2028

Figure 8: Global Precision Medicine Market (by Ecosystem), 2017 and 2028

Figure 9: Global Precision Medicine Market, (by Application), 2017 and 2028

Figure 10: Global Precision Medicine Market (by Region), 2017 and 2028

Figure 11: Notable Areas of Strategic Focus across Influential Countries

Figure 12: Strategies Incorporated to Expand the Global Reach

Figure 13: Precision Medicine Funding for Academic Institutions and Research Organizations

Figure 14: A Persuasive Market Entry Strategy for Diagnostics and Pharma & Biotech Companies to Capitalize on Precision Medicine

Figure 15: Plausible Market Penetration Strategy to Shape the Future of Healthcare

Figure 16: Go To Market Strategy

Figure 17: Value Assessment Frameworks

Figure 18: Product/Service Promotion Strategies

Figure 19: Precision Medicine: A Trigger to Unfold Innovative Business Model

Figure 20: Fixable Gaps in the Field of Precision Medicine

Figure 21: Estimated Ratios of Cost per Quality-Adjusted Life Year (QALY) Gained for Precision or Personalized Medicine Tests

Figure 22: Impact of Precision Medicine on Researchers, Manufacturers, and Consumers

Figure 23: Opportunities and Challenges for Researchers, Providers, and Patients

Figure 1.1: Precision Medicine Approach

Figure 1.2: Evolution of Precision Medicine Technology

Figure 1.3: Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy

Figure 1.4: Precision Medicine: Remodeling Framework

Figure 1.5: Precision Medicine: Enabling Technologies

Figure 1.6: Structured Big Data Reporting Benefits

Figure 1.7: Generalized Process for the Microarray

- Figure 2.1: Market Dynamics of Global Precision Medicine Market
- Figure 2.2: Total Number of Genetic Products in Market
- Figure 2.3: Total Number of Genetic Products in Market
- Figure 2.4: % of Patients Whose Tumors Were Driven by Certain Genetic Mutations That Could Be Targets for Specific Drugs
- Figure 2.5: Gene Therapy Products in Pipeline
- Figure 2.6: Sales Forecast for Gene Therapy Products (Yescarta and Kymriah), \$ Million
- Figure 2.7: Precision Medicine Deals (2010-2017)
- Figure 3.1: Competitive Landscape, January 2012-December 2018
- Figure 3.2: Share of Key Developments and Strategies (January 2012-December 2018)
- Figure 3.3: Joint Ventures, Partnerships, Agreements, and Collaborations Share by Companies (January 2012-December 2018)
- Figure 3.4: Product launches, Enhancements, and Upgradation Share by Companies (January 2012-December 2018)
- Figure 3.5: Product Approvals Share by Companies (January 2012-December 2018)
- Figure 3.6: Merger and Acquisitions Share by Companies (January 2012-December 2018)
- Figure 3.7: Business Expansion Share by Companies (January 2012-December 2018)
- Figure 3.8: Other Developments Share by Companies (January 2012-December 2018)
- Figure 3.9: Market Share Analysis by Applied Sciences, 2017
- Figure 3.10: Market Share Analysis by Precision Diagnostics, 2017
- Figure 3.11: Market Share Analysis by Precision Therapeutics, 2017
- Figure 3.12: Market Share Analysis by Digital Health and IT, 2017
- Figure 3.13: Porter's Five Forces Analysis
- Figure 3.14: Definition of Suppliers and Buyers in the Precision Medicine Market
- Figure 3.15: Bargaining Power of Suppliers: Overall Impact, 2015-2028
- Figure 3.16: Bargaining Power of Buyers: Overall Impact, 2015-2028
- Figure 3.17: Threat of New Entrant: Overall Impact, 2015-2028
- Figure 3.18: Threat of Substitute Products: Overall Impact, 2014-2028
- Figure 3.19: Intensity of Competitive Rivalry: Overall Impact, 2015-2028
- Figure 3.20: Supply Chain Analysis: Global Precision Medicine Market
- Figure 4.1: Patent Analysis
- Figure 4.2: Role of FDA in Advancing Precision Medicine
- Figure 5.1: Precision Medicine: The Ecosystem
- Figure 5.2: Global Precision Medicine Market (by Ecosystem)
- Figure 5.3: Global Precision Medicine Market (by Ecosystem), 2017-2028
- Figure 5.4: Global Precision Medicine Market (by Applied Sciences)
- Figure 5.5: Global Precision Medicine Market (by Applied Sciences), 2017-2028

Figure 5.6: Precision Medicine: Omics Sciences

Figure 5.7: Global Precision Medicine Applied Sciences Market (by Type), 2017-2028

Figure 5.8: Precision Medicine: Genomics

Figure 5.9: Global Precision Medicine Genomics Market, 2017-2028

Figure 5.10: Global Precision Medicine Genomics Market (by Technology), 2017-2028

Figure 5.11: Global Precision Medicine PCR Market, 2017-2028

Figure 5.12: Global Precision Medicine PCR Market (by Product Type), 2017-2028

Figure 5.13: Global Precision Medicine PCR Market (by End User), 2017-2028

Figure 5.14: Global Precision Medicine PCR Market (by Region), 2017-2028

Figure 5.15: Evolution of Next-Generation Sequencing

Figure 5.16: Global Precision Medicine NGS Market, 2017-2028

Figure 5.17: Global Precision Medicine PM NGS Market (by Product Type), 2017-2028

Figure 5.18: Global Precision Medicine NGS Market (by Technology), 2017-2028

Figure 5.19: Global Precision Medicine NGS Market (by End User), 2017-2028

Figure 5.20: Global Precision Medicine NGS Market (by Region), 2017-2028

Figure 5.21: Global Precision Medicine Genome Editing Market, 2017-2028

Figure 5.22: Global Precision Medicine Genome Editing Market (by Product Type),
2017-2028

Figure 5.23: Global Precision Medicine Genome Editing Market (by End User),
2017-2028

Figure 5.24: Global Precision Medicine Genome Editing Market (by Region), 2017-2028

Figure 5.25: Global Precision Medicine Other Technologies Market, 2017-2028

Figure 5.26: Global Precision Medicine Other Technologies Market (by Region),
2017-2028

Figure 5.27: Clinical Applications of Pharmacogenomics Testing

Figure 5.28: Role of Biomarkers in Pharmacogenomics

Figure 5.29: Role of FDA In Pharmacogenomics

Figure 5.30: Global Precision Medicine Pharmacogenomics Market, 2017-2028

Figure 5.31: Global Precision Medicine Pharmacogenomics Market (by
Pharmacogenomics Services), 2017-2028

Figure 5.32: Global Precision Medicine Pharmacogenomics Market (by End User),
2017-2028

Figure 5.33: Global Precision Medicine Pharmacogenomics Market (by Region),
2017-2028

Figure 5.34: Global Precision Medicine Other Applied Sciences Market, 2017-2028

Figure 5.35: Precision Medicine: Diagnostics

Figure 5.36: Global Precision Medicine Market (by Precision Diagnostics)

Figure 5.37: Global Precision Medicine Market (by Precision Diagnostics), 2017-2028

Figure 5.38: Global Precision Medicine Diagnostics Market (by Type), 2017-2028

- Figure 5.39: General Workflow of a Molecular Diagnostic Assay
- Figure 5.40: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics)
- Figure 5.41: Global Precision Medicine Molecular Diagnostics Market, 2017-2028
- Figure 5.42: Global Precision Medicine Molecular Diagnostics Market (by Type), 2017-2028
- Figure 5.43: Benefits and Risks Associated with NIPT
- Figure 5.44: Global Precision Medicine NIPT Market, 2017-2028
- Figure 5.45: Global Precision Medicine NIPT Market (by Platform), 2017-2028
- Figure 5.46: Global Precision Medicine NIPT Market (by Region), 2017-2028
- Figure 5.47: Drug and Companion Diagnostics Development Process
- Figure 5.48: Benefits and Risks Associated with Companion Diagnostics
- Figure 5.49: Global Precision Medicine Companion Diagnostics Market, 2017-2028
- Figure 5.50: Global Precision Medicine Companion Diagnostics Market (by Technology), 2017-2028
- Figure 5.51: Global Precision Medicine Companion Diagnostics Market (by Indication), 2017-2028
- Figure 5.52: Global Precision Medicine Companion Diagnostics Market (by Region), 2017-2028
- Figure 5.53: Clinical Applications of Liquid Biopsy
- Figure 5.54: Global Precision Medicine Liquid Biopsy Market, 2017-2028
- Figure 5.55: Global Precision Medicine Liquid Biopsy Market (by Indication), 2017-2028
- Figure 5.56: Global Precision Medicine Liquid Biopsy Market (by Region), 2017-2028
- Figure 5.57: Global Precision Medicine Other Molecular Diagnostics Market, 2017-2028
- Figure 5.58: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2017-2028
- Figure 5.59: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2017-2028
- Figure 5.60: Global Precision Medicine Medical Imaging Market, 2017-2028
- Figure 5.61: Global Precision Medicine Medical Imaging Market (by Type), 2017-2028
- Figure 5.62: Global Precision Medicine Medical Imaging Market (by Region), 2017-2028
- Figure 5.63: Global Precision Medicine Imaging Analytics Market, 2017-2028
- Figure 5.64: Global Precision Medicine CADx Market, 2017-2028
- Figure 5.65: Global Precision Medicine Digital Health and Information Technology Market, 2017-2028
- Figure 5.66: Global Precision Medicine Digital Health and Information Technology Market (by Type), 2017-2028
- Figure 5.67: Global Precision Medicine Digital Health and Information Technology Market (by End User), 2017-2028
- Figure 5.68: Global Precision Medicine Digital Health and Information Technology

Market (by Region), 2017-2028

Figure 5.69: Global Precision Medicine CDSS Market, 2017-2028

Figure 5.70: Big Data Attributes

Figure 5.71: Global Precision Medicine Big Data Analytics Market, 2017-2028

Figure 5.72: Big Data Analytics: Key Benefits

Figure 5.73: Global Precision Medicine IT Infrastructure Market, 2017-2028

Figure 5.74: Global Precision Medicine IT Infrastructure Market (by Type), 2017-2028

Figure 5.75: Global Precision Medicine Genomics Informatics Market, 2017-2028

Figure 5.76: Global Precision Medicine Genomics Informatics Market (by Product Type), 2017-2028

Figure 5.77: Global Precision Medicine In-Silico Informatics Market, 2017-2028

Figure 5.78: Global Precision Medicine Mobile Health Market, 2017-2028

Figure 5.79: Global Precision Medicine Therapeutics Market, 2017-2028

Figure 5.80: Global Precision Medicine Therapeutics Market (by Type), 2017-2028

Figure 5.81: Global Precision Medicine Clinical Trials Market, 2017-2028

Figure 5.82: Global Precision Medicine Clinical Trials Market (by Region), 2017-2028

Figure 5.83: Types of Cell Therapy

Figure 5.84: Global Precision Medicine Cell Therapy Market, 2017-2028

Figure 5.85: Global Precision Medicine Cell Therapy Market (by Region), 2017-2028

Figure 5.86: Global Precision Medicine Drug Discovery and Research Market, 2017-2028

Figure 5.87: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028

Figure 5.88: Types of Gene Therapy

Figure 5.89: Types of Gene Therapy

Figure 5.90: Global Precision Medicine Gene Therapy Market, 2017-2028

Figure 5.91: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028

Figure 6.1: Therapeutic Areas in Precision Medicine

Figure 6.2: Global Precision Medicine Applications Market, 2017-2028

Figure 6.3: Types of Cancer

Figure 6.4: Global Precision Medicine Oncology Market, 2017-2028

Figure 6.5: Global Precision Medicine Infectious Diseases Market, 2017-2028

Figure 6.6: Number of Deaths by Top 18 Infectious Diseases, 2015

Figure 6.7: Global Precision Medicine Neurology/Physiatry Market, 2017-2028

Figure 6.8: Global Precision Medicine Cardiovascular Market, 2017-2028

Figure 6.9: Global Precision Medicine Lifestyle and Endocrinology Market, 2017-2028

Figure 6.10: Global Precision Medicine Gastroenterology Market, 2017-2028

Figure 6.11: Global Precision Medicine Other Applications Market, 2017-2028

- Figure 7.1: Global Precision Medicine Market (by Region)
- Figure 7.2: Global Precision Medicine Market (by Region), 2017 and 2028
- Figure 7.3: Global Precision Medicine Market (by Region), 2017-2028
- Figure 7.4: North America Precision Medicine Market, 2017-2028
- Figure 7.5: North America Precision Medicine Market (by Country), 2017-2028
- Figure 7.6: North America Precision Medicine Market (by Ecosystem), 2017-2028
- Figure 7.7: The U.S. Precision Medicine Market, 2017-2028
- Figure 7.8: Canada Precision Medicine Market, 2017-2028
- Figure 7.9: Europe Precision Medicine Market, 2017-2028
- Figure 7.10: Europe Precision Medicine Market (by Country), 2017-2028
- Figure 7.11: Europe Precision Medicine Market (by Ecosystem), 2017-2028
- Figure 7.12: Germany Precision Medicine Market, 2017-2028
- Figure 7.13: France Precision Medicine Market, 2017-2028
- Figure 7.14: Italy Precision Medicine Market, 2017-2028
- Figure 7.15: The U.K. Precision Medicine Market, 2017-2028
- Figure 7.16: Spain Precision Medicine Market, 2017-2028
- Figure 7.17: Rest-of-Europe Precision Medicine Market, 2017-2028
- Figure 7.18: Asia-Pacific Precision Medicine Market, 2017-2028
- Figure 7.19: Asia-Pacific Precision Medicine Market (by Country), 2017-2028
- Figure 7.20: Asia-Pacific Precision Medicine Market (by Ecosystem), 2017-2028
- Figure 7.21: China Precision Medicine Market, 2017-2028
- Figure 7.22: Japan Precision Medicine Market, 2017-2028
- Figure 7.23: Australia Precision Medicine Market, 2017-2028
- Figure 7.24: India Precision Medicine Market, 2017-2028
- Figure 7.25: Rest-of- Asia-Pacific Precision Medicine Market, 2017-2028
- Figure 7.26: Latin America Precision Medicine Market, 2017-2028
- Figure 7.27: Latin America Precision Medicine Market (by Country), 2017-2028
- Figure 7.28: Latin America Precision Medicine Market (by Ecosystem), 2017-2028
- Figure 7.29: Brazil Precision Medicine Market, 2017-2028
- Figure 7.30: Mexico Precision Medicine Market, 2017-2028
- Figure 7.31: Rest-of-Latin America Precision Medicine Market, 2017-2028
- Figure 7.32: Rest-of-the-World Precision Medicine Market, 2017-2028
- Figure 7.33: Major Countries in the Middle East Precision Medicine Market
- Figure 8.1: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017
- Figure 8.2: Abbott Laboratories: Revenue (by Business Segment), 2015-2017
- Figure 8.3: Abbott Laboratories: Revenue (by Region), 2015-2017
- Figure 8.4: Abbott Laboratories R&D Expenditure, 2015-2017
- Figure 8.5: Amgen Inc.: Overall Financials, 2015-2017
- Figure 8.6: Amgen Inc.: Revenue (by Region), 2015-2017

- Figure 8.7: Amgen Inc. R&D Expenditure, 2014-2017
- Figure 8.8: ANGLE plc: Overall Financials, 2015-2017
- Figure 8.9: ANGLE plc: Revenue (by Region), 2015-2017
- Figure 8.10: ANGLE plc R&D Expenditure, 2014-2017
- Figure 8.11: Astellas Pharma Inc.: Overall Financials, 2015-2017
- Figure 8.12: Astellas Pharma Inc.: Revenue (by Region), 2015-2017
- Figure 8.13: Astellas Pharma Inc. R&D Expenditure, 2015-2017
- Figure 8.14: Astra Zeneca PLC : Overall Financials, 2015-2017
- Figure 8.15: Astra Zeneca PLC: Revenue (by Business Segment), 2015-2017
- Figure 8.16: Astra Zeneca PLC: Revenue (by Region), 2015-2017
- Figure 8.17: Astra Zeneca PLC R&D Expenditure, 2014-2017
- Figure 8.18: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017
- Figure 8.19: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2015-2017
- Figure 8.20: Bio-Rad Laboratories, Inc: Revenue (by Region), 2015-2017
- Figure 8.21: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017
- Figure 8.22: bioMérieux SA.: Overall Financials, 2015-2017
- Figure 8.23: bioMérieux SA.: Revenue (by Business Segment), 2015-2017
- Figure 8.24: bioMérieux SA.: Revenue (by Region), 2015-2017
- Figure 8.25: bioMérieux SA. R&D Expenditure, 2014-2017
- Figure 8.26: Bristol-Myers Squibb Company: Overall Financials, 2015-2017
- Figure 8.27: Bristol-Myers Squibb Company: Revenue (by Region), 2015-2017
- Figure 8.28: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017
- Figure 8.29: Canon Inc.: Overall Financials, 2015-2017
- Figure 8.30: Canon Inc.: Revenue (by Segment), 2015-2017
- Figure 8.31: Canon Inc.: Revenue (by Region), 2015-2017
- Figure 8.32: Canon Inc.: R&D Expenditure, 2015-2017
- Figure 8.33: Danaher Corporation: Overall Financials, 2015-2017
- Figure 8.34: Danaher Corporation: Revenue (by Business Segment), 2015-2017
- Figure 8.35: Danaher Corporation: Revenue (by Region), 2015-2017
- Figure 8.36: Danaher Corporation R&D Expenditure, 2014-2017
- Figure 8.37: Eli Lilly and Company Limited: Overall Financials, 2015-2017
- Figure 8.38: Eli Lilly and Company Limited: Revenue (by Business Segment), 2015-2017
- Figure 8.39: Eli Lilly and Company Limited: Revenue (by Region), 2015-2017
- Figure 8.40: Eli Lilly and Company Limited R&D Expenditure, 2014-2017
- Figure 8.41: F.Hoffman-LA Roche AG: Overall Financials, 2015-2017
- Figure 8.42: F.Hoffman-LA Roche AG: Revenue (by Business Segment), 2015-2017
- Figure 8.43: F.Hoffman-LA Roche AG : Revenue (by Region), 2015-2017
- Figure 8.44: F.Hoffman-LA Roche AG R&D Expenditure, 2014-2017

- Figure 8.45: GE Corporation Limited: Overall Financials, 2015-2017
- Figure 8.46: GE Corporation: Revenue (by Business Segment), 2015-2017
- Figure 8.47: GE Corporation: Revenue (by Region), 2015-2017
- Figure 8.48: GE Corporation R&D Expenditure, 2014-2017
- Figure 8.49: Gilead Sciences, Inc.: Overall Financials, 2015-2017
- Figure 8.50: Gilead Sciences, Inc.: Revenue (by Business Segment), 2015-2017
- Figure 8.51: Gilead Sciences, Inc.: Revenue (by Region), 2015-2017
- Figure 8.52: Gilead Sciences, Inc. R&D Expenditure, 2014-2017
- Figure 8.53: GlaxoSmithKline Plc: Overall Financials, 2015-2017
- Figure 8.54: GlaxoSmithKline Plc: Revenue (by Business Segment), 2015-2017
- Figure 8.55: GlaxoSmithKline Plc: Revenue (by Region), 2015-2017
- Figure 8.56: GlaxoSmithKline Plc R&D Expenditure, 2014-2017
- Figure 8.57: IBM Corporation: Overall Financials, 2015-2017
- Figure 8.58: IBM Corporation: Revenue (by Business Segment), 2015-2017
- Figure 8.59: IBM Corporation: Revenue (by Region), 2015-2017
- Figure 8.60: IBM Corporation R&D Expenditure, 2014-2017
- Figure 8.61: Illumina, Inc.: Overall Financials, 2015-2017
- Figure 8.62: Illumina, Inc.: Revenue (by Business Segment), 2015-2017
- Figure 8.63: Illumina, Inc.: Revenue (by Region), 2015-2017
- Figure 8.64: Illumina, Inc. R&D Expenditure, 2014-2017
- Figure 8.65: Johnson and Johnson: Overall Financials, 2015-2017
- Figure 8.66: Johnson and Johnson: Revenue (by Business Segment), 2015-2017
- Figure 8.67: Johnson and Johnson Revenue (by Region), 2015-2017
- Figure 8.68: Johnson and Johnson R&D Expenditure, 2014-2017
- Figure 8.69: Konica Minolta, Inc.: Overall Financials, 2015-2017
- Figure 8.70: Konica Minolta, Inc.: Revenue (by Segment), 2015-2017
- Figure 8.71: Konica Minolta, Inc.: Revenue (by Region), 2015-2017
- Figure 8.72: Konica Minolta, Inc.: R&D Expenditure, 2015-2017
- Figure 8.73: Lab Corporation of America: Overall Financials, 2015-2017
- Figure 8.74: Lab Corporation of America: Revenue (by Business Segment), 2015-2017
- Figure 8.75: Lab Corporation of America: Revenue (by Region), 2015-2017
- Figure 8.76: MDx Health, Inc.: Overall Financials, 2015-2017
- Figure 8.77: MDx Health, Inc. R&D Expenditure, 2014-2017
- Figure 8.78: Merck & Co., Inc.: Overall Financials, 2015-2017
- Figure 8.79: Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017
- Figure 8.80: Merck & Co., Inc.: Revenue (by Region), 2015-2017
- Figure 8.81: Merck & Co., Inc. R&D Expenditure, 2015-2017
- Figure 8.82: Myriad Genetics, Inc.: Overall Financials, 2015-2017
- Figure 8.83: Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017

- Figure 8.84: Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
- Figure 8.85: Myriad Genetics, Inc. R&D Expenditure, 2015-2017
- Figure 8.86: Novartis AG: Overall Financials, 2015-2017
- Figure 8.87: Novartis AG: Revenue (by Business Segment), 2015-2017
- Figure 8.88: Novartis AG: Revenue (by Region), 2015-2017
- Figure 8.89: Novartis AG R&D Expenditure, 2015-2017
- Figure 8.90: Oracle Corporation: Overall Financials, 2015-2017
- Figure 8.91: Oracle Corporation: Revenue (by Region), 2015-2017
- Figure 8.92 Oracle Corporation R&D Expenditure, 2015-2017
- Figure 8.93: Pacific Biosciences of California, Inc.: Overall Financials, 2015-2017
- Figure 8.94: Pacific Biosciences of California, Inc.: Revenue (by Region), 2015-2017
- Figure 8.95: Pacific Biosciences of California, Inc. R&D Expenditure, 2015-2017
- Figure 8.96: Pfizer, Inc.: Overall Financials, 2015-2017
- Figure 8.97: Pfizer, Inc.: Revenue (by Business Segment), 2015-2017
- Figure 8.98: Pfizer, Inc.: Revenue (by Region), 2015-2017
- Figure 8.99: Pfizer, Inc. R&D Expenditure, 2015-2017
- Figure 8.100: QIAGEN N.V: Overall Financials, 2015-2017
- Figure 8.101: QIAGEN N.V: Revenue (by Business Segment), 2015-2017
- Figure 8.102: QIAGEN N.V: Revenue (by Region), 2015-2017
- Figure 8.103: QIAGEN N.V R&D Expenditure, 2015-2017
- Figure 8.104: Quest Diagnostics Inc.: Overall Financials, 2015-2017
- Figure 8.105: Quest Diagnostics Inc.: Revenue (by Business Segment), 2015-2017
- Figure 8.106: Quest Diagnostics Inc.: Revenue (by Region), 2015-2017
- Figure 8.107: Sanofi SA: Overall Financials, 2015-2017
- Figure 8.108: Sanofi SA: Revenue (by Business Segment), 2015-2017
- Figure 8.109: Sanofi SA: Revenue (by Region), 2015-2017
- Figure 8.110 Sanofi SA R&D Expenditure, 2015-2017
- Figure 8.111: Sysmex Corporation: Overall Financials, 2015-2017
- Figure 8.112: Sysmex Corporation: Revenue (by Business Segment), 2015-2017
- Figure 8.113: Sysmex Corporation R&D Expenditure, 2015-2017
- Figure 8.114: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2015-2017
- Figure 8.115: Teva Pharmaceuticals Industries Ltd.: Revenue (by Business Segment), 2015-2017
- Figure 8.116: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2015-2017
- Figure 8.117: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2015-2017
- Figure 8.118: Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
- Figure 8.119: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
- Figure 8.120: Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017

Figure 8.121 Thermo Fisher Scientific Inc. R&D Expenditure, 2015-2017

Figure 8.122: TrovaGene, Inc.: Overall Financials, 2015-2017

Figure 9.1: Global Precision Medicine Market Segmentation

Figure 9.2: Figure Scope

Figure 9.3: Key data points from primary resources

Figure 9.4: Key data points from secondary resources

Figure 9.5: Top-down Approach (Segment-wise Analysis)

Figure 9.6: Bottom-Up Approach (Segmental Analysis)

Figure 9.7: Research Methodology Snapshot

Figure 9.8: Assumptions and Limitations

Figure 9.9: Considered Factors for Data Prediction and Modelling

I would like to order

Product name: Global Precision Medicine Market: Focus on Precision Medicine Ecosystem, Applications, 13 Countries Mapping, and Competitive Landscape - Analysis and Forecast: 2018-2028

Product link: <https://marketpublishers.com/r/G29969471DC6EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G29969471DC6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

